BERLIN and SEATTLE, Aug. 5, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported financial results for the second quarter and first half of 2008, ended June 30, 2008, and provided a corporate update.
